TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00911521
Drug: human papillomavirus vaccination (Gardasil)
Normalized name: human papillomavirus
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
Study: NCT01683149
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan will be given by mouth as outlined in treatment arm.
Study: NCT01683149
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be given by mouth as outlined in treatment arm.
Study: NCT03094182
Drug: Iron Isomaltoside 1000
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
Study: NCT01068756
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
Study: NCT01068756
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
Study: NCT00438776
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg to 15mg daily
Study: NCT00438776
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to olanzapine
Study: NCT03628040
Drug: Ropivacaine Injection [Naropin]
Normalized name: ROPivacaine Injection [Naropin]
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine will be injected in the erector spinae plane
Study: NCT00058773
Drug: Infusion of EBV Specific Cytotoxic T-Lymphocytes
Normalized name: rabbit anti-human T-lymphocyte globulin
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart.
Study: NCT01428414
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
Study: NCT01428414
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75mg/m2, iv d1, 8,15. qw; 4-6 cycles
Study: NCT01428414
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2, iv d1, q3w, 4-6 cycles
Study: NCT01428414
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 2, qw, iv d1, 8,15. 4-6 cycles
Study: NCT00882362
Drug: OPC-14597 (Aripiprazole)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered orally once daily, 3 to 15 mg daily, 52 weeks
Study: NCT02132689
Drug: Actilyse (Thrombolytic therapy)
Normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02132689
Drug: Heparine (Standard anticoagulation therapy)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00634621
Drug: Hexaminolevulinate (Hexvix)
DrugBank: Hexaminolevulinate (DB06261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
Study: NCT04329130
Drug: Chidamide, Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
Study: NCT03030157
Drug: pirarubicin(THP)
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00024336
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01493778
Drug: turoctocog alfa
Normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
Study: NCT00026234
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intra-arterially
Study: NCT00026234
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intra-arterially
Study: NCT00026234
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00145314
Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLOX every 2nd week
Study: NCT00145314
Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FLOX every 2nd week Cetuximab weekly
Study: NCT00145314
Drug: FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly.
Study: NCT00813059
Drug: Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
Study: NCT00989001
Drug: Vernakalant
Normalized name: vernakalant
DrugBank: Vernakalant (DB06217)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
Study: NCT00818805
Drug: Olopatadine 0.1%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one drop in one eye
Study: NCT00818805
Drug: Tranilast 0.5%
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop in one eye
Study: NCT04210180
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
Study: NCT01179334
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
Study: NCT01179334
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
Study: NCT02352090
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One tablet orally for 9 weeks, continuous use
Study: NCT00193128
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
Study: NCT00193128
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
Study: NCT03077711
Drug: Trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
Study: NCT03077711
Drug: Methenamine hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
Study: NCT00151528
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01654328
Drug: Sodium chloride tablets
Normalized name: Sodium Chloride Tablets
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
Study: NCT04126460
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab is a type of PD-1 antibody
Study: NCT04456322
Drug: RT plus Nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
Study: NCT04456322
Drug: RT plus Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
Study: NCT02318407
Drug: AMG 403
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 403 for the treatment of subjects with osteoarthritis
Study: NCT02191098
Drug: ALT-803
Normalized name: ALT-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
Study: NCT00147485
Drug: AG-024322
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01565148
Drug: iCo-007 350 mcg
Normalized name: iCo-007
DrugBank: iCo-007 (DB05268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
Study: NCT01565148
Drug: iCo-007 700 mcg
Normalized name: iCo-007
DrugBank: iCo-007 (DB05268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
Study: NCT01565148
Drug: iCo-007 350 mcg and Laser
Normalized name: iCo-007
DrugBank: iCo-007 (DB05268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
Study: NCT01565148
Drug: Ranibizumab and iCo-007 350 mcg
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
Study: NCT01847872
Drug: IPV IM Needle
Normalized name: NEEDLE
DrugBank: Pine needle oil (pinus mugo) (DB11276)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01847872
Drug: IPV ID Needle
Normalized name: NEEDLE
DrugBank: Pine needle oil (pinus mugo) (DB11276)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04583267
Drug: tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration
Normalized name: emtricitabine
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
Study: NCT03908333
Drug: Paclitaxel protein-bound
Normalized name: Paclitaxel Protein-Bound
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
Study: NCT03908333
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
Study: NCT03908333
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study: NCT00838253
Drug: Istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
Study: NCT00838253
Drug: Istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
Study: NCT00838253
Drug: Istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
Study: NCT03932981
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
Study: NCT02647268
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin, 10-5M solution
Study: NCT02647268
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulphate, 3.5mM solution
Study: NCT00529659
Drug: Comparator: MK-0773
DrugBank: MK-0773 (DB16244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0773 50 mg tablets twice daily, 6 month treatment period
Study: NCT01823133
Drug: gemigliptin only
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 50mg qd on day 1\~7
Study: NCT03005678
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: active treatment group
Study: NCT03005678
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparator
Study: NCT00268671
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004056
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004056
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004056
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004056
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004056
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04321031
Drug: PF-06865571
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00555412
Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total)
Normalized name: loxapine 10 MG
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loxapine aerosol inhalation high dose regimen (30 mg total)
Study: NCT00555412
Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loxapine aerosol inhalation middle dose regimen (20 mg total)
Study: NCT00555412
Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total)
Normalized name: nicotine 0.875 MG/HR [Nicoderm C-Q]
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loxapine aerosol inhalation low dose regimen (15 mg total)
Study: NCT01077635
Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
Study: NCT01538719
Drug: Rilonacept
Normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
Study: NCT03010631
Drug: Cohort 1: Lubiprostone Capsule, Fasted
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone soft gelatin capsule administered under fasted conditions
Study: NCT03010631
Drug: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Study: NCT03010631
Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fed
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone sprinkle formulation administered under fed conditions
Study: NCT03010631
Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fasted
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Study: NCT00018603
Drug: guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01169103
Drug: recombinant human growth hormone (rhGH)
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
Study: NCT02724358
Drug: Rg3
Normalized name: RG3039
DrugBank: D-157495 (DB16938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, BID, maintained though Month 12.
Study: NCT00879788
Drug: Ramipril 10mg capsules
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02096471
Drug: PD-0325901
Normalized name: PD-0325901
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432354
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03061227
Drug: Intravenous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Randomized application of glucagon or saline during oral glucose tolerance test
Study: NCT01337791
Drug: Telbivudine treatment
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
Study: NCT04321031
Drug: PF-05221304
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02634541
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biologic drug
Study: NCT00295724
Drug: Bicifadine
Normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01582815
Drug: JNJ-40411813
Normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
Study: NCT01339104
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
Study: NCT01040494
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
Study: NCT02176005
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin is used alone or associated to DAV132
Study: NCT04622111
Drug: Metformin hydrochloride 750 mg
Normalized name: metformin hydrochloride 750 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
Study: NCT03549975
Drug: Botulinum Toxin Type A 100 unit/Vial (Product)
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin type A injection followed by functional electrical stimulation
Study: NCT02531152
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01939171
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02728310
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.